PNC Financial Services Group
NKTR icon

PNC Financial Services Group’s Nektar Therapeutics NKTR Stock Holding History

PNC Financial Services Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-27
Closed -$273 – 5020
2025
Q1 		$273 Buy
+27
New +$353 ﹤0.01% 4739
2024
Q1 		– Sell
-7
Closed -$57 – 4774
2023
Q4 		$57 Buy
+7
New +$53 ﹤0.01% 4550
2023
Q3 		– Sell
-26
Closed -$222 – 4700
2023
Q2 		$222 Buy
26
+3
+13% +$32 ﹤0.01% 4659
2023
Q1 		$246 Sell
23
-126
-85% -$3.81K ﹤0.01% 4583
2022
Q4 		$5.04K Sell
149
-1,146
-88% -$55.5K ﹤0.01% 3991
2022
Q3 		$63K Buy
1,295
+770
+147% +$45.8K ﹤0.01% 2822
2022
Q2 		$29K Buy
525
+42
+9% +$2.65K ﹤0.01% 3306
2022
Q1 		$38K Sell
483
-181
-27% -$26.8K ﹤0.01% 3259
2021
Q4 		$134K Buy
664
+249
+60% +$54K ﹤0.01% 2495
2021
Q3 		$112K Buy
415
+16
+4% +$3.85K ﹤0.01% 2574
2021
Q2 		$102K Sell
399
-7
-2% -$1.94K ﹤0.01% 2642
2021
Q1 		$122K Buy
406
+68
+20% +$21.2K ﹤0.01% 2451
2020
Q4 		$88K Buy
338
+7
+2% +$1.81K ﹤0.01% 2571
2020
Q3 		$83K Sell
331
-228
-41% -$71.7K ﹤0.01% 2427
2020
Q2 		$195K Sell
559
-2
-0.4% -$624 ﹤0.01% 1947
2020
Q1 		$151K Sell
561
-447
-44% -$138K ﹤0.01% 1975
2019
Q4 		$327K Buy
1,008
+279
+38% +$80.9K ﹤0.01% 1751
2019
Q3 		$200K Sell
729
-932
-56% -$342K ﹤0.01% 2136
2019
Q2 		$887K Buy
1,661
+923
+125% +$463K ﹤0.01% 1338
2019
Q1 		$371K Sell
738
-14
-2% -$8.3K ﹤0.01% 1793
2018
Q4 		$371K Buy
752
+30
+4% +$18.1K ﹤0.01% 1712
2018
Q3 		$660K Sell
722
-195
-21% -$166K ﹤0.01% 1519
2018
Q2 		$671K Sell
917
-1,821
-67% -$2.1M ﹤0.01% 1484
2018
Q1 		$4.36M Sell
2,738
-551
-17% -$710K ﹤0.01% 775
2017
Q4 		$2.95M Buy
3,289
+1,253
+62% +$741K ﹤0.01% 913
2017
Q3 		$733K Buy
2,036
+217
+12% +$67.9K ﹤0.01% 1421
2017
Q2 		$534K Sell
1,819
-137
-7% -$39.6K ﹤0.01% 1587
2017
Q1 		$688K Sell
1,956
-90
-4% -$20.2K ﹤0.01% 1456
2016
Q4 		$377K Buy
2,046
+440
+27% +$89.5K ﹤0.01% 1742
2016
Q3 		$414K Buy
1,606
+174
+12% +$44.8K ﹤0.01% 1654
2016
Q2 		$306K Sell
1,432
-510
-26% -$114K ﹤0.01% 1832
2016
Q1 		$401K Sell
1,942
-1,841
-49% -$354K ﹤0.01% 1673
2015
Q4 		$957K Buy
3,783
+238
+7% +$48.9K ﹤0.01% 1230
2015
Q3 		$584K Sell
3,545
-99
-3% -$17.5K ﹤0.01% 1476
2015
Q2 		$683K Buy
3,644
+87
+2% +$15K ﹤0.01% 1466
2015
Q1 		$587K Sell
3,557
-791
-18% -$163K ﹤0.01% 1540
2014
Q4 		$1.01M Buy
4,348
+16
+0.4% +$3.42K ﹤0.01% 1200
2014
Q3 		$786K Sell
4,332
-67
-2% -$12.8K ﹤0.01% 1222
2014
Q2 		$846K Sell
4,399
-545
-11% -$96.4K ﹤0.01% 1154
2014
Q1 		$899K Buy
4,944
+2,201
+80% +$436K ﹤0.01% 1112
2013
Q4 		$468K Buy
2,743
+960
+54% +$155K ﹤0.01% 1421
2013
Q3 		$279K Buy
1,783
+980
+122% +$181K ﹤0.01% 1677
2013
Q2 		$140K Buy
+803
New +$123K ﹤0.01% 1940

Other funds holding NKTR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PNC Financial Services Group's NKTR Position: Q2 2025 in Review

PNC Financial Services Group sold out of Nektar Therapeutics (NKTR) in Q2 2025, closing a stake of 27 shares — an estimated $273 sold.

PNC Financial Services Group first reported a position in NKTR in Q2 2013 and held it in 43 quarters. The position peaked at $4.36M in Q1 2018. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.

  • PNC Financial Services Group reported no remaining Nektar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • PNC Financial Services Group sold 27 Nektar Therapeutics shares in Q2 2025, an estimated $273.
  • PNC Financial Services Group first reported a position in Nektar Therapeutics in Q2 2013 and held it in 43 quarters.
  • PNC Financial Services Group's Nektar Therapeutics position peaked at $4.36M in Q1 2018.
  • 109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.

Based on PNC Financial Services Group's 13F filing for Q2 2025, filed 8 Aug 2025.